Our story

The story of the technology started in 2005 when John Nieland, then Head of Immunology at Medigene AG, and colleagues Markus Hörer and Hildegard Büning, discovered how to replace peptides on the surface of a modified adenovirus with antigens to induce and enhance a specific antibody response. The AAVLP inventions were patented in the following years, but the potential was never commercialised as Medigene decided to focus on other projects and John Nieland left the company to pursue new opportunities. In 2014 John Nieland joined Professor Søren Nielsen at Aalborg University and the idea to develop a company around AAVLP was again ignited. John Nieland and Søren Nielsen approached Medigene with their idea and started the discussions about an in-licensing agreement while also exploring funding options. During this process, the team was expanded to include Preben Bruun-Nyzell. 2A Pharma AB was founded on 12 December 2016 in Malmö, Sweden. Shortly thereafter, the company’s first employee, Jeanette Prangsgaard, joined as Project Manager for our lead project and two years after, Mathilde Sanden, joined as Project Manager for the projects in the Research and Development stage.

OUR TEAM

Preben Bruun-Nyzell

CEO

Read More

John Nieland

COO

Read More

Jeanette Prangsgaard

Project Manager

Read More

Mathilde Sanden

Project Manager

Read More

BOARD OF DIRECTORS

Peter Lainevool, Chairman

CEO S.A.B. Corporate Finance

Read More

Jens Renstrup, M.D., MBA

CMO SpringWorks Therapeutics

Read More

Preben Bruun-Nyzell

CEO 2A Pharma

Read More

John Nieland

COO 2A Pharma

Read More